Skip to main content

Table 2 The dosing of frequently used aminoglycosides and glycopeptides in European NICUs

From: High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination

Drug PMA group No of cases Median unit dose (quartiles; mg/kg/dose) Unit dose range (mg/kg/dose) Median dosing interval (quartiles; h) BNFC/the Blue book unit dose (mg/kg/dose) BNFC/the Blue book dose interval (h) Neofax unit dose (mg/kg/dose) Neofax dose interval (h) c
Gentamicin <32 weeks 21 4.6 (4.2–5.0) 3.3–6.6 36 (24–36); 24–48 4–5 (2.5a) 36 (18–24a) 4–5 36 (24–48)
N = 139 ≥32 weeks 118 4.4 (3.9–4.8) 1.2–19.4 24 (24–24); 12–36 4–5 (2.5a) 24 (12–18a) 4 24 (24–36)
Amikacin e PNA 0–28 days 34 15.1 (8.8–17.4) 3.1–18.5 24 (24–36); 12–48 15 (7.5a) 24 (12) 15–18 24–48
N = 35 PNA >28 days 1 7.5 12   15 (7.5a) 24 (12) 15 24
Vancomycin b <29 weeks 5 9.5 9.0–10.0 21 (11–24); 8–24 15 24 10 (15d) 12–18
N = 40 29–35 weeks 14 10.0 (9.3–14.3) 4.8–15.6 15 (12–24); 2–48 15 12 10 (15d) 8–12
  >35 weeks 21 11.2 (9.7–14.7) 9.0–18.9 12 (8–12); 8–24 15 8 10 (15d) 6–12
  1. PMA – postmenstrual age; PNA – postnatal age.
  2. a – multiple daily dosing recommendation regimen is given in parenthesis; for gentamicin multiple daily dosing regimen recommendations are for PMA limits <29 weeks; 29–35 weeks and >35 weeks and have been adjusted accordingly.
  3. b – 9 infants received vancomycin continuous infusion and are excluded from this analysis.
  4. c – different PMA/ PNA groups are applied compared to BNFC, the interval range includes all applicable in the respective PMA/PNA range.
  5. d – meningitis dose.
  6. e – please note, that in contrast to gentamicin and vancomycin dosing based on PMA, current amikacin dosing recommendation is based on PNA.